Company intelligence / Profile preview

Fifty 1 Labs

Melbourne, Florida, United States

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Fifty 1 Labs completed the world's largest Sickle Cell Disease study using real-world data and AI-driven analytics, enabling gene-based and repurposed therapy development; the GeneScape platform delivers rapid target identification and drug repurposing for biothreats and rare diseases, with active expansion into government and pharma partnerships but no public clinical efficacy readouts as of October 2025.

Therapeutic areas: HematologyInfectious DiseasesOtherRare Diseases
Modalities: Small moleculeGene therapymRNA-based drugsBiologic
Industry: Biotech

Partnerships

The Gates FoundationUniversity of Pittsburgh School of MedicineStellenbosch University Centre for Infectious DiseasesGilead Sciences (noted as past client via Genetic Networks)

Beyond the preview

Go deeper on Fifty 1 Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fifty 1 Labs.

Explore the full profile